Brolucizumab

布西珠单抗

Report date: 2026/03/13 20:02:36

Base Information

Drug NameBrolucizumab
Drug Alias Name布西组单抗Brolucizumab-dbll布洛赛珠单抗BrolucizumabumBeovu +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaPolypoidal choroidal vasculopathyDiabetes Mellitus +[13] 
Global Approved IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Approved Indications in ChinaDiabetic macular oedema
Original Approved Country/TerritoryUnited States
Original Approved Date2019/10/07
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma AgAlcon
China Registration ClassN/A

Develop Information

Active CompaniesYeungnam UniversityNovartis Pharma AgNovartis Pharma Stein Ag +[8] 
Inactive CompaniesBenha UniversityAlcon
Active IndicationsDiabetic macular oedemaPolypoidal choroidal vasculopathyDiabetes Mellitus +[7] 
Inactive IndicationsChoroidal NeovascularizationRetinal Vein OcclusionRetinal Diseases +[6] 

Other Information

ATC CodeS01LA06
Related LinksWikipediaDrugBankKEGG